Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CanSino Confirms Immune Response For Coronavirus Vaccine But Safety Concerns Remain

Phase II Results Published

Executive Summary

Latest clinical results show that CanSino's adeno-associated virus coronavirus vaccine appears to be safe and that it induced an immune response in most subjects.

You may also be interested in...



Novartis Not Tempted To Join COVID-19 Vaccines Race

While the traditional players such as Pfizer and GSK, as well as newcomer AstraZeneca, are hot in pursuit of a COVID-19 vaccine, the Swiss major is sticking to drugs, the area where "we do have deep expertise," CEO Vas Narasimhan told journalists.

New Pfizer/BioNTech COVID-19 Vaccine Data Confirm Prior Results, Show T-Cell Boost

While data from small trials are difficult to compare, it appears that T-cell responses to BNT162b1 may be stronger than those reported so far for Moderna’s competing mRNA-based vaccine. 

Solid Phase I Results For AstraZeneca COVID-19 Vaccine, But Two Doses Needed To Hit Efficacy Goal

Oxford’s long-awaited early stage study produces solid safety and efficacy results, but lags Pfizer/BioNTech and Moderna’s mRNA candidates for antibody response.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1131690

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel